270 related articles for article (PubMed ID: 34981143)
1. Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area.
Wu Y; Chen Y; Zhu P; Ye B; Lu Y; Shi J; Tan Y; Zhao Y; Yu J; Lai X; Lan J; Si T; Ni L; Huang H; Luo Y
Ann Hematol; 2022 Mar; 101(3):631-641. PubMed ID: 34981143
[TBL] [Abstract][Full Text] [Related]
2. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.
Wu Y; Huang H; Luo Y
Front Immunol; 2020; 11():610500. PubMed ID: 33613534
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of resolved hepatitis B virus infection combined with nephrotic syndrome in a patient after allogeneic haematopoietic stem cell transplantation.
Zhang JW; Zhang XZ; Sun YL; Long B; Wang XZ; Li XD
BMC Infect Dis; 2019 Jan; 19(1):57. PubMed ID: 30651070
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center.
Buzo BF; Ramos JF; Marques Rossetti RA; Salles N; Mendrone-Júnior A; Rocha V; de Seixas Santos Nastri AC
Transpl Infect Dis; 2020 Apr; 22(2):e13243. PubMed ID: 31901206
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
6. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor.
Knöll A; Boehm S; Hahn J; Holler E; Jilg W
J Viral Hepat; 2007 Jul; 14(7):478-83. PubMed ID: 17576389
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
Liao YP; Jiang JL; Zou WY; Xu DR; Li J
World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
[TBL] [Abstract][Full Text] [Related]
9. A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience.
Shang J; Wang H; Sun J; Fan Z; Huang F; Zhang Y; Jiang Q; Dai M; Xu N; Lin R; Liu Q
Bone Marrow Transplant; 2016 Apr; 51(4):581-6. PubMed ID: 26752138
[TBL] [Abstract][Full Text] [Related]
10. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B.
Lee HL; Jang JW; Han JW; Lee SW; Bae SH; Choi JY; Han NI; Yoon SK; Kim HJ; Lee S; Cho SG; Min CK; Kim DW; Lee JW
Dig Dis Sci; 2019 Oct; 64(10):2992-3000. PubMed ID: 30982209
[TBL] [Abstract][Full Text] [Related]
11. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor.
Cerva C; Colagrossi L; Maffongelli G; Salpini R; Di Carlo D; Malagnino V; Battisti A; Ricciardi A; Pollicita M; Bianchi A; Picardi A; Cudillo L; Cerretti R; De Angelis G; Cantonetti M; Andreoni M; Perno CF; Arcese W; Svicher V; Sarmati L
Clin Microbiol Infect; 2016 Nov; 22(11):946.e1-946.e8. PubMed ID: 27475741
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country.
Murt A; Elverdi T; Eskazan AE; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Soysal T
Ann Hematol; 2020 Nov; 99(11):2671-2677. PubMed ID: 32737632
[TBL] [Abstract][Full Text] [Related]
13. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal.
Cerva C; Maffongelli G; Svicher V; Salpini R; Colagrossi L; Battisti A; Mariotti B; Cerretti R; Cudillo L; Sarmati L
BMC Infect Dis; 2017 Aug; 17(1):566. PubMed ID: 28806922
[TBL] [Abstract][Full Text] [Related]
15. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review.
Gentile G; Antonelli G
Viruses; 2019 Nov; 11(11):. PubMed ID: 31717647
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study.
Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lau EHY; Cheung KS; Lie AKW; Lai CL; Kwong YL; Yuen MF
Hepatology; 2017 May; 65(5):1451-1461. PubMed ID: 28027590
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors.
Hui CK; Lie A; Au WY; Ma SY; Leung YH; Zhang HY; Sun J; Cheung WW; Chim CS; Kwong YL; Liang R; Lau GK
Am J Transplant; 2005 Jun; 5(6):1437-45. PubMed ID: 15888052
[TBL] [Abstract][Full Text] [Related]
18. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper.
Sarmati L; Andreoni M; Antonelli G; Arcese W; Bruno R; Coppola N; Gaeta GB; Galli M; Girmenia C; Mikulska M; Pane F; Perno CF; Picardi M; Puoti M; Rambaldi A; Svicher V; Taliani G; Gentile G
Clin Microbiol Infect; 2017 Dec; 23(12):935-940. PubMed ID: 28668466
[TBL] [Abstract][Full Text] [Related]
19. [Change in the serologic markers of hepatitis B after allogenic hematopoietic stem-cell transplantation].
Woo SY; Cho SH; Lee SM; Koh MB; Noh CH; Kim CW; Choi JY; Yang JM; Han JY; Lee YS
Korean J Hepatol; 2009 Jun; 15(2):131-9. PubMed ID: 19581765
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Cessation of Nucleos(t)ide Analog Administration on Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study.
Onozawa M; Kusumoto S; Najima Y; Hashimoto H; Okada K; Tamaki M; Tanaka M; Sato T; Takahashi T; Hatano K; Onodera K; Moriuchi Y; Yakushijin K; Kanda J; Nagafuji K; Ogata M; Nakano N; Tamori A; Mizokami M
Transplant Cell Ther; 2024 Mar; 30(3):330.e1-330.e8. PubMed ID: 38242442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
